Technical Analysis for WXXWY - Wuxi Biologics Cayman Inc ADR
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Gapped Down | Weakness | 0.00% | |
20 DMA Resistance | Bearish | -4.78% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -4.78% | |
MACD Bullish Signal Line Cross | Bullish | -4.78% | |
Narrow Range Bar | Range Contraction | -4.78% | |
Gapped Up | Strength | -4.78% | |
Up 3 Days in a Row | Strength | -4.78% | |
Up 4 Days in a Row | Strength | -4.78% | |
Up 5 Days in a Row | Strength | -4.78% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -2.69% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Rose Above Previous Day's High | 2 days ago |
Up 3% | 2 days ago |
Up 2% | 2 days ago |
Up 1% | 2 days ago |
20 DMA Resistance | 2 days ago |
Get a Trading Sidekick!
Wuxi Biologics Cayman Inc ADR Description
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. As of June 30, 2018, there were a total of 187 integrated projects, including 98 projects in pre-clinical development stage, 78 projects in early-phase (phase I and II) clinical development, 10 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2021, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network.
Classification
Sector: Other
Industry: Other
Keywords: Manufacturing Biotechnology Pharmaceutical Industry Life Sciences Biopharmaceutical Pharmacy F 18 Wuxi Biopharmaceutical Product Contract Research Organizations Wuxi Biologics Value Proposition
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 38.0 |
52 Week Low | 10.5 |
Average Volume | 601,594 |
200-Day Moving Average | 22.8299 |
50-Day Moving Average | 14.6473 |
20-Day Moving Average | 13.5784 |
10-Day Moving Average | 12.8972 |
Average True Range | 0.7406 |
RSI | 42.20 |
ADX | 19.18 |
+DI | 27.7448 |
-DI | 38.5097 |
Chandelier Exit (Long, 3 ATRs) | 13.1582 |
Chandelier Exit (Short, 3 ATRs) | 14.0718 |
Upper Bollinger Bands | 15.2632 |
Lower Bollinger Band | 11.8936 |
Percent B (%b) | 0.33 |
BandWidth | 24.8159 |
MACD Line | -0.5885 |
MACD Signal Line | -0.6355 |
MACD Histogram | 0.047 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 13.5850 | ||||
Resistance 3 (R3) | 13.6367 | 13.4933 | 13.4875 | ||
Resistance 2 (R2) | 13.4933 | 13.3444 | 13.4675 | 13.4550 | |
Resistance 1 (R1) | 13.2467 | 13.2523 | 13.1750 | 13.1950 | 13.4225 |
Pivot Point | 13.1033 | 13.1033 | 13.0675 | 13.0775 | 13.1033 |
Support 1 (S1) | 12.8567 | 12.9544 | 12.7850 | 12.8050 | 12.5775 |
Support 2 (S2) | 12.7133 | 12.8623 | 12.6875 | 12.5450 | |
Support 3 (S3) | 12.4667 | 12.7133 | 12.5125 | ||
Support 4 (S4) | 12.4150 |